Cargando…

Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). METHODS: Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every 3 weeks. The primar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Shreyaskumar, von Mehren, Margaret, Reed, Damon R., Kaiser, Pamela, Charlson, John, Ryan, Christopher W., Rushing, Daniel, Livingston, Michael, Singh, Arun, Seth, Rahul, Forscher, Charles, D'Amato, Gina, Chawla, Sant P., McCarthy, Sharon, Wang, George, Parekh, Trilok, Knoblauch, Roland, Hensley, Martee L., Maki, Robert G., Demetri, George D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/ https://www.ncbi.nlm.nih.gov/pubmed/31173362 http://dx.doi.org/10.1002/cncr.32117

Ejemplares similares

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin
por: Jones, Robin L., et al.
Publicado: (2019)

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021)

Safely combining trabectedin with radiotherapy to treat myxoid liposarcoma
por: Chen, Mark, et al.
Publicado: (2019)

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin
por: Amant, Frédéric, et al.
Publicado: (2015)

Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin
por: Turpin, Anthony, et al.
Publicado: (2014)

Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
por: Tamiya, Hironari, et al.
Publicado: (2020)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma
por: De Sanctis, Rita, et al.
Publicado: (2015)

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016)

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report
por: Pedrinaci, Irene Zarcos, et al.
Publicado: (2012)

Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin
por: Strippoli, Sabino, et al.
Publicado: (2013)

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
por: Cesne, A L, et al.
Publicado: (2013)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma [Corrigendum]
Publicado: (2016)

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma
por: Nathenson, Michael J, et al.
Publicado: (2018)

Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma
por: Lamm, W., et al.
Publicado: (2010)

Complete remission of a reccurrent mesenteric liposarcoma with rare histological features following the administration of trabectedin
por: TSOUKALAS, N., et al.
Publicado: (2014)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report
por: Matsuda, Shogo, et al.
Publicado: (2020)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
por: Fabbroni, Chiara, et al.
Publicado: (2021)

Efficacy of PD-1 inhibitors combined with pegylated liposomal doxorubicin and dacarbazine compared with liposomal doxorubicin and dacarbazine in advanced leiomyosarcoma patients: a retrospective, single-institutional cohort study
por: Tan, Zhichao, et al.
Publicado: (2022)

Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report
por: Nteli, Viktoria-Anna, et al.
Publicado: (2018)

Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report
por: Rastogi, Sameer, et al.
Publicado: (2019)

Trabectedin and Radiation Therapy for Cardiac Metastasis From Leiomyosarcoma: A Case Report and Review of the Literature
por: Tortorelli, Ilaria, et al.
Publicado: (2022)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine
por: Cannella, Lucia, et al.
Publicado: (2023)

Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin
por: Haslbauer, Ferdinand
Publicado: (2018)

Long-Time Progression-Free Survival with Trabectedin in Chemorefractory Metastatic Leiomyosarcoma of the Retroperitoneum: A Case Report
por: Reichinger, Andreas
Publicado: (2023)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
por: Blay, Jean-Yves, et al.
Publicado: (2019)

Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience
por: Steinbrecher, Oskar, et al.
Publicado: (2023)

Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline
por: Maruzzo, Marco, et al.
Publicado: (2016)

Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome()()
por: Barlin, Joyce N., et al.
Publicado: (2015)

Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model
por: Kiyuna, Tasuku, et al.
Publicado: (2018)

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma
por: Gadducci, Angiolo, et al.
Publicado: (2018)

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
por: Rubio, María Jesús, et al.
Publicado: (2020)

Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma
por: Liu, Wenshuai, et al.
Publicado: (2020)

Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis
por: Jiang, Guan, et al.
Publicado: (2014)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Induction of p53-independent apoptosis by ectopic expression of HOXA5 in human liposarcomas
por: Lee, Dhong Hyun, et al.
Publicado: (2015)

Retroperitoneal Malignant Mesenchymoma: A Case of Mesenchymal Mixed Tumor with Osteosarcoma, Leiomyosarcoma, Liposarcoma and Fibrosarcoma
por: Choi, Jung Eun, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_jgkkit1hpe0qn95lb3knaevpdj